Jonathan A Peng, MD
Cardiovascular Disease (Cardiology) · Santa Rosa
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- Not verified
- Not the same as out of network.
- Offices
- 11
Offices
11 locations · Sutter Bay Medical Foundation · 3,783 clinicians in this group
Hospitals listed: Sutter Lakeside Hospital · Sutter Santa Rosa Regional Hospital. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Peng’s office to ask if they take your plan before you enroll.
California Medical Board record
Licence A109735 · Current
Licensed to practise in California · since 2009 · expires 2027-05-31 · Indiana University School of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Sutter Lakeside HospitalLakeport, CACritical Access Hospital · Voluntary non-profit - Private · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 76% would definitely recommend itOverall rating: 4 of 5 starsNo measure marked better or worse than the national rate
- Sutter Santa Rosa Regional HospitalSanta Rosa, CAAcute Care Hospital · Voluntary non-profit - Other · Has an emergency department · Birthing-friendlyPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 3 of 5 · 79% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Central Line Associated Bloodstream Infection (ICU + select Wards): 0, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.157, Oct 2024 – Sep 2025
See every measure and the patient survey for Sutter Lakeside Hospital
Behind the star rating — Deaths: 0 better, 4 the same, 0 worse of 4 measures. Safety: 0 better, 1 the same, 0 worse of 1 measures. Readmissions: 1 better, 5 the same, 0 worse of 6 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Death rate for COPD patientsComplications and deaths | 8.7 · 46 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.7 · 94 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14.2 · 133 cases | None | Jul 2022 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.9 · 379 cases | None | Jul 2024 – Jun 2025 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.8 · 31 cases | None | Apr 2023 – Mar 2025 |
| Clostridium Difficile (C.Diff)Infections | 1.249 | No different | Oct 2024 – Sep 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.9 · 72 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -25.4 · 92 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -37.9 · 137 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.3 · 109 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.3 · 36 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.7 · 47 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13.2 (9.9 to 17.3) · 564 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.9 (0.6 to 1.3) · 52 cases | No different | Jan 2024 – Dec 2024 |
What patients said (209 patients answered, 18% of those asked)
| Cleanliness | 5 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 4 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 4 |
| Recommend hospital | 4 |
| Room was "always" clean | 83% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 79% |
| Staff "always" explained | 70% |
| Yes, staff "did" give patients this information | 90% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 72% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 85% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 82% |
| Nurses "always" explained things so they could understand | 73% |
| Nurses "always" listened carefully | 78% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 63% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 58% |
| Yes, staff "did" give patients information about possible symptoms | 91% |
See every measure and the patient survey for Sutter Santa Rosa Regional Hospital
Behind the star rating — Deaths: 1 better, 6 the same, 0 worse of 7 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 1 better, 8 the same, 1 worse of 10 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.157 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.03 (0.08 to 1.99) · 1,147 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.03 (0.69 to 1.37) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 162.53 (108.3 to 216.76) · 54 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 6.8 · 85 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 11.8 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10.5 · 316 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 14 · 296 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.6 · 142 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.9 · 1,971 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.26 (0.06 to 0.47) · 4,946 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.23 (0.03 to 0.43) · 4,974 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 4.99 (2.93 to 7.06) · 1,288 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.5 (0 to 3.15) · 532 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (0.82 to 3.9) · 1,214 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 9.87 (2.35 to 17.39) · 558 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 8.01 (4.29 to 11.73) · 522 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.6 (0.14 to 3.05) · 337 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.18 (0 to 0.89) · 4,064 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.1 · 206 cases | None | Apr 2023 – Mar 2025 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.626 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.299 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 14.1 · 186 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 21 · 342 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -4.1 · 184 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -14 · 352 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -17.4 · 309 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.2 · 309 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 7.2 (5.1 to 9.8) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.6 (8.8 to 15) · 259 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.3 · 215 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.8 · 100 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 14 (10.8 to 18) · 1,275 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.9 to 1.4) · 702 cases | No different | Jan 2024 – Dec 2024 |
What patients said (752 patients answered, 22% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 2 |
| Communication about medicines | 2 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 67% |
| Nurses "always" communicated well | 79% |
| Doctors "always" communicated well | 75% |
| Staff "always" explained | 57% |
| Yes, staff "did" give patients this information | 88% |
| Yes, staff "did" give patients information about help after discharge | 87% |
| Doctors "always" explained things so they could understand | 70% |
| Doctors "always" listened carefully | 74% |
| Doctors "always" treated them with courtesy and respect | 82% |
| Patients who gave a rating of "9" or "10" (high) | 76% |
| Staff "always" explained new medications | 69% |
| Nurses "always" explained things so they could understand | 74% |
| Nurses "always" listened carefully | 75% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 55% |
| "YES", patients would definitely recommend the hospital | 79% |
| Staff "always" explained possible side effects | 45% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$328,526
Medicare paid this office $328,526 for 1,341 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 408 | $67,682 | $102 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 263 | $44,053 | $162 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 97 | $38,249 | $390 |
| New patient visit (45+ min) | 239 | $28,623 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $21,355 | $96 |
See all 30 services
| Return visit (30+ min) | 408 | $67,682 | $102 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 263 | $44,053 | $162 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 97 | $38,249 | $390 |
| New patient visit (45+ min) | 239 | $28,623 | $120 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 104 | $21,355 | $96 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 307 | $16,373 | $50 |
| Long return visit (40+ min) | 78 | $15,828 | $145 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 98 | $14,786 | $76 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 70 | $9,633 | $138 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 631 | $9,540 | $11 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 379 | $8,648 | $13 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 125 | $7,084 | $55 |
| Critical care, first 30-74 minutes | 24 | $6,681 | $171 |
| Ultrasound of heart with probe in esophagus, with report | 70 | $6,272 | $85 |
| Evaluation of cardiac rhythm monitor system, remote up to 30 days | 11 | $4,620 | $89 |
| External shock to heart to regulate heart beat | 46 | $4,533 | $89 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 68 | $4,109 | $60 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 142 | $2,875 | $20 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 37 | $2,353 | $64 |
| Programming of dual lead pacemaker system | 16 | $1,400 | $64 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 32 | $1,123 | $18 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 24 | $962 | $21 |
| Ultrasound of heart blood flow, valves and chambers | 48 | $738 | $14 |
| Ultrasound of heart, follow-up | 34 | $709 | $18 |
| Heart rhythm recording of continous external ekg over 8-15 days | 69 | $689 | $10 |
| Telephone or internet assessment with verbal and written report by consulting physician, 11-20 minutes | 13 | $375 | $29 |
| Injection, regadenoson, 0.1 mg | 27 | $345 | None |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 16 | $245 | $15 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 74 | $194 | $2 |
| Ultrasound of heart blood flow, valves and chambers, follow-up | 24 | $138 | $6 |
Who their Medicare patients are
1,341 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 13% · Women 52% · Also on Medicaid 27% · Health risk score 1.61. At or below the middle of the specialty; the typical cardiology clinician is at 1.71.
Conditions among them: High blood pressure 75% · Coronary heart disease 41% · Atrial fibrillation 38% · Heart failure 33% · Diabetes 30% · Chronic kidney disease 28% · Depression 24% · COPD 21% · Cancer 15% · Stroke 13% · Dementia 8%.
The office billed $1,758,044, Medicare allowed $441,339 and paid $328,526; for 4,928 services of 55 kinds; $345 of it was for drugs given in the office and $328,181 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 1,341 | 4,928 | 75 | 1.61 | $1,758,044 | $328,526 |
| 2023 | 731 | 1,849 | 74 | 1.47 | $670,954 | $141,953 |
| 2022 | 70 | 90 | 65 | 1.47 | $11,911 | $2,072 |
| 2021 | 72 | 133 | 68 | 1.96 | $13,414 | $2,695 |
| 2020 | 84 | 132 | 67 | 2.60 | $10,184 | $2,096 |
| 2019 | 86 | 140 | 66 | 2.34 | $11,273 | $1,887 |
| 2018 | 86 | 143 | 68 | 2.42 | $12,670 | $1,912 |
| 2017 | 64 | 101 | 66 | 2.47 | $9,656 | $1,958 |
| 2016 | 59 | 95 | 68 | 2.36 | $7,725 | $1,591 |
| 2015 | 70 | 103 | 64 | 2.55 | $11,798 | $2,250 |
| 2014 | 32 | 42 | 71 | 2.03 | $4,821 | $1,191 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 23 services
| Return visit (30+ min) | 262 | $37,598 | $108 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 125 | $21,394 | $170 |
| New patient visit (45+ min) | 134 | $18,208 | $136 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 37 | $15,180 | $410 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $6,891 | $98 |
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 113 | $6,629 | $54 |
| Technetium tc-99m tetrofosmin, diagnostic, per study dose | 37 | $5,564 | $76 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | 374 | $5,073 | $12 |
| Long return visit (40+ min) | 17 | $2,774 | $154 |
| Exercise or drug-induced heart stress test with electrocardiogram (ecg) with supervision and review by physician | 43 | $2,501 | $57 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 18 | $1,943 | $108 |
| Ultrasound of heart with probe in esophagus, with report | 20 | $1,749 | $87 |
| Heart rhythm review and interpretation of continous external ekg over 8-15 days | 51 | $1,077 | $21 |
| Nuclear medicine studies of heart muscle at rest and with stress and spect | 14 | $886 | $63 |
| Initial hospital care with straightforward or low level of medical decision making, per day at least 40 minutes | 11 | $753 | $68 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system or implantable defibrillator system, remote up to 90 days | 21 | $466 | $20 |
| Ultrasound of heart, follow-up | 18 | $455 | $21 |
| Heart rhythm recording of continous external ekg over 8-15 days | 40 | $454 | $11 |
| Evaluation of single, dual, multiple lead or leadless pacemaker system, remote up to 90 days | 17 | $447 | $24 |
| Heart rhythm review, and interpretation of continous external ekg over more than 48 hours up to 7 days | 16 | $293 | $18 |
| Ultrasound of heart blood flow, valves and chambers | 16 | $236 | $15 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 25 | $155 | $6 |
| Ultrasound of heart with color-depicted blood flow, rate and valve function | 20 | $51 | $3 |
2022: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 39 | $264 | $6 |
2021: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 67 | $664 | $7 |
2020: 2 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 11 | $662 | $60 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 66 | $632 | $6 |
2019: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 67 | $639 | $6 |
2018: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 63 | $661 | $6 |
2017: 2 services
| Ultrasound of heart with color-depicted blood flow, rate, direction and valve function | 18 | $773 | $43 |
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 44 | $312 | $6 |
2016: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 40 | $308 | $6 |
2015: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 49 | $388 | $6 |
2014: 1 service
| Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | 21 | $186 | $7 |
Medicaid work
$52,058 in 2024
Medicaid paid $52,058 for 934 billed services this clinician did in 2024, up to 62 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 291 | $26,659 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 344 | $9,376 |
| Return visit (30+ min) | 217 | $7,649 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 36 | $5,686 |
| CARDIOVASCULAR STRESS TEST | 14 | $1,852 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; review and interpretation | 20 | $606 |
| External electrocardiographic recording for more than 7 days up to 15 days by continuous rhythm recording and storage; recording (includes connection and initial recording) | 12 | $231 |
| 2024 | 934 | 7 | 62 | $52,058 |
| 2023 | 995 | 7 | 111 | $47,945 |
| 2022 | 794 | 2 | 102 | $1,956 |
| 2021 | 878 | 2 | 95 | $2,531 |
| 2020 | 527 | 2 | 86 | $1,473 |
| 2019 | 129 | 1 | 42 | $833 |
| 2018 | 44 | 1 | 15 | $595 |
See the largest Medicaid services in earlier years
2023
| Echocardiography, transthoracic, real-time with image documentation (2D), includes M-mode recording, when performed, complete, with spectral Doppler echocardiography, and with color flow Doppler echocardiography | 197 | $28,460 |
| OFF/OP CNSLTJ NEW/EST MOD 40 | 48 | $7,460 |
| Electrocardiogram, routine ECG with at least 12 leads; with interpretation and report | 209 | $6,763 |
| Return visit (30+ min) | 110 | $3,413 |
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 368 | $1,271 |
| External electrocardiographic recording for more than 48 hours up to 7 days by continuous rhythm recording and storage; review and interpretation | 13 | $498 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 50 | $80 |
2022
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 704 | $1,923 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 90 | $33 |
2021
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 813 | $2,443 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 65 | $88 |
2020
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 501 | $1,456 |
| Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | 26 | $16 |
2019
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 129 | $833 |
2018
| Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only | 44 | $595 |
Drugs they prescribed that Part D paid
$443,303
Pharmacies billed $443,303 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 2,377) in 2024. At or below the middle of the specialty; the typical cardiology clinician is at 0%.
1,965 generic and 412 brand-name prescriptions · $443,303 in drug cost · 26 antibiotic prescriptions to 20 people.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Eliquis | 192 | $215,630 | $1,123 |
| Entresto | 71 | $72,040 | $1,015 |
| Jardiance | 65 | $62,453 | $961 |
| Xarelto | 24 | $26,494 | $1,104 |
| Farxiga | 15 | $17,662 | $1,177 |
See all 37 drugs
| Eliquis | 192 | $215,630 | $1,123 |
| Entresto | 71 | $72,040 | $1,015 |
| Jardiance | 65 | $62,453 | $961 |
| Xarelto | 24 | $26,494 | $1,104 |
| Farxiga | 15 | $17,662 | $1,177 |
| Brilinta | 20 | $14,408 | $720 |
| Metoprolol | 252 | $3,140 | $12 |
| Atorvastatin | 302 | $2,291 | $8 |
| Rosuvastatin | 102 | $1,788 | $18 |
| Amiodarone | 47 | $1,179 | $25 |
| Dofetilide | 12 | $1,005 | $84 |
| Lisinopril | 92 | $919 | $10 |
| Carvedilol | 141 | $845 | $6 |
| Losartan | 87 | $764 | $9 |
| Bisoprolol | 27 | $664 | $25 |
| Isosorbide Mononitrate Er | 70 | $637 | $9 |
| Furosemide | 92 | $598 | $6 |
| Amlodipine Besylate | 140 | $597 | $4 |
| Spironolactone | 81 | $548 | $7 |
| Flecainide Acetate | 21 | $535 | $25 |
| Ezetimibe | 34 | $500 | $15 |
| Diltiazem 24hr Er (Cd) | 25 | $487 | $19 |
| Bumetanide | 13 | $406 | $31 |
| Sotalol Af | 11 | $401 | $36 |
| Metoprolol | 58 | $284 | $5 |
| Hydralazine | 25 | $263 | $11 |
| Losartan-Hydrochlorothiazide | 26 | $220 | $8 |
| Clopidogrel | 14 | $219 | $16 |
| Lisinopril-Hydrochlorothiazide | 20 | $170 | $8 |
| Benazepril | 16 | $163 | $10 |
| Pravastatin | 14 | $158 | $11 |
| Sotalol | 14 | $154 | $11 |
| Hydrochlorothiazide | 47 | $140 | $3 |
| Nitroglycerin | 13 | $120 | $9 |
| Digoxin | 11 | $113 | $10 |
| Amoxicillin | 22 | $58 | $3 |
| Atenolol | 13 | $28 | $2 |
Year by year
| 2024 | 2,377 | 505 | 0% (0) | 17% | $443,303 |
| 2023 | 2,143 | 550 | 0% (0) | 16% | $260,959 |
| 2022 | 2,162 | 501 | 0% (0) | 17% | $211,014 |
| 2021 | 1,845 | 457 | 0% (0) | 17% | $174,085 |
| 2020 | 1,421 | 356 | 0% (0) | 15% | $104,146 |
| 2019 | 1,133 | 353 | 0% (0) | 18% | $94,501 |
| 2018 | 1,174 | 327 | 0% (0) | 20% | $89,659 |
| 2017 | 1,552 | 383 | None | 24% | $117,542 |
| 2016 | 1,639 | 349 | 0% (0) | 31% | $102,833 |
| 2015 | 1,109 | 282 | None | None | $67,159 |
| 2014 | 273 | 116 | 0% (0) | 27% | $19,074 |
| 2013 | 104 | 35 | None | 20% | $3,324 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 34 drugs
| Entresto | 67 | $95,687 | $1,428 |
| Eliquis | 53 | $51,750 | $976 |
| Jardiance | 41 | $27,397 | $668 |
| Pradaxa | 65 | $19,465 | $299 |
| Bisoprolol | 106 | $3,120 | $29 |
| Flecainide Acetate | 69 | $2,817 | $41 |
| Atorvastatin | 177 | $2,720 | $15 |
| Metoprolol | 151 | $2,558 | $17 |
| Furosemide | 164 | $2,064 | $13 |
| Lisinopril | 120 | $1,667 | $14 |
| Isosorbide Dinitrate | 15 | $1,616 | $108 |
| Amiodarone | 37 | $1,555 | $42 |
| Amlodipine Besylate | 118 | $1,424 | $12 |
| Isosorbide Mononitrate Er | 76 | $1,299 | $17 |
| Hydralazine | 31 | $1,167 | $38 |
| Ranolazine Er | 13 | $1,156 | $89 |
| Losartan | 90 | $1,125 | $12 |
| Sotalol | 43 | $995 | $23 |
| Carvedilol | 88 | $892 | $10 |
| Spironolactone | 91 | $831 | $9 |
| Metoprolol | 80 | $785 | $10 |
| Rosuvastatin | 44 | $744 | $17 |
| Diltiazem 24hr Er (Cd) | 19 | $703 | $37 |
| Nitroglycerin | 21 | $697 | $33 |
| Clopidogrel | 31 | $602 | $19 |
| Potassium Chloride | 12 | $527 | $44 |
| Digoxin | 21 | $452 | $22 |
| Lisinopril-Hydrochlorothiazide | 27 | $379 | $14 |
| Diltiazem | 11 | $336 | $31 |
| Hydrochlorothiazide | 33 | $306 | $9 |
| Losartan-Hydrochlorothiazide | 22 | $256 | $12 |
| Ezetimibe | 11 | $182 | $17 |
| Amoxicillin | 40 | $177 | $4 |
| Azithromycin | 11 | $67 | $6 |
2022: 31 drugs
| Entresto | 73 | $76,769 | $1,052 |
| Pradaxa | 81 | $39,922 | $493 |
| Brilinta | 15 | $18,771 | $1,251 |
| Flecainide Acetate | 103 | $5,062 | $49 |
| Bisoprolol | 98 | $4,606 | $47 |
| Metoprolol | 145 | $2,935 | $20 |
| Amiodarone | 70 | $2,667 | $38 |
| Furosemide | 165 | $2,236 | $14 |
| Hydralazine | 26 | $1,947 | $75 |
| Lisinopril | 139 | $1,930 | $14 |
| Atorvastatin | 117 | $1,913 | $16 |
| Sotalol | 66 | $1,691 | $26 |
| Isosorbide Mononitrate Er | 100 | $1,398 | $14 |
| Amlodipine Besylate | 107 | $1,303 | $12 |
| Metoprolol | 123 | $1,289 | $10 |
| Losartan | 95 | $1,239 | $13 |
| Spironolactone | 102 | $1,076 | $11 |
| Ranolazine Er | 11 | $879 | $80 |
| Carvedilol | 81 | $864 | $11 |
| Digoxin | 29 | $821 | $28 |
| Torsemide | 26 | $753 | $29 |
| Clopidogrel | 33 | $695 | $21 |
| Potassium Chloride | 15 | $666 | $44 |
| Losartan-Hydrochlorothiazide | 20 | $487 | $24 |
| Hydrochlorothiazide | 40 | $453 | $11 |
| Lisinopril-Hydrochlorothiazide | 28 | $327 | $12 |
| Nitroglycerin | 21 | $311 | $15 |
| Rosuvastatin | 21 | $309 | $15 |
| Atenolol | 14 | $198 | $14 |
| Amoxicillin | 28 | $160 | $6 |
| Azithromycin | 13 | $75 | $6 |
2021: 26 drugs
| Entresto | 42 | $46,230 | $1,101 |
| Pradaxa | 71 | $43,605 | $614 |
| Brilinta | 13 | $13,523 | $1,040 |
| Flecainide Acetate | 126 | $6,226 | $49 |
| Bisoprolol | 76 | $3,569 | $47 |
| Metoprolol | 139 | $3,194 | $23 |
| Hydralazine | 34 | $2,876 | $85 |
| Amiodarone | 55 | $2,067 | $38 |
| Furosemide | 146 | $1,956 | $13 |
| Atorvastatin | 126 | $1,835 | $15 |
| Sotalol | 55 | $1,622 | $29 |
| Lisinopril | 100 | $1,334 | $13 |
| Metoprolol | 130 | $1,257 | $10 |
| Isosorbide Mononitrate Er | 73 | $1,122 | $15 |
| Digoxin | 36 | $1,101 | $31 |
| Losartan | 76 | $917 | $12 |
| Spironolactone | 71 | $767 | $11 |
| Amlodipine Besylate | 55 | $652 | $12 |
| Carvedilol | 68 | $646 | $9 |
| Nitroglycerin | 19 | $543 | $29 |
| Clopidogrel | 26 | $540 | $21 |
| Lisinopril-Hydrochlorothiazide | 39 | $478 | $12 |
| Torsemide | 11 | $375 | $34 |
| Hydrochlorothiazide | 30 | $362 | $12 |
| Atenolol | 18 | $231 | $13 |
| Amoxicillin | 19 | $116 | $6 |
2020: 23 drugs
| Pradaxa | 74 | $45,215 | $611 |
| Entresto | 11 | $11,896 | $1,081 |
| Flecainide Acetate | 104 | $4,758 | $46 |
| Bisoprolol | 58 | $2,726 | $47 |
| Atorvastatin | 113 | $1,985 | $18 |
| Metoprolol | 84 | $1,764 | $21 |
| Dilt-Xr | 21 | $1,754 | $84 |
| Hydralazine | 41 | $1,745 | $43 |
| Furosemide | 103 | $1,354 | $13 |
| Sotalol | 45 | $1,249 | $28 |
| Isosorbide Mononitrate Er | 68 | $1,138 | $17 |
| Lisinopril | 73 | $1,063 | $15 |
| Digoxin | 31 | $1,009 | $33 |
| Metoprolol | 102 | $961 | $9 |
| Clopidogrel | 35 | $858 | $25 |
| Losartan | 74 | $839 | $11 |
| Spironolactone | 58 | $737 | $13 |
| Carvedilol | 65 | $665 | $10 |
| Amiodarone | 20 | $597 | $30 |
| Nitroglycerin | 17 | $373 | $22 |
| Lisinopril-Hydrochlorothiazide | 27 | $335 | $12 |
| Amlodipine Besylate | 27 | $295 | $11 |
| Amoxicillin | 21 | $131 | $6 |
2019: 25 drugs
| Pradaxa | 81 | $46,195 | $570 |
| Flecainide Acetate | 83 | $4,614 | $56 |
| Bisoprolol | 80 | $3,888 | $49 |
| Dilt-Xr | 21 | $1,798 | $86 |
| Atorvastatin | 62 | $1,500 | $24 |
| Klor-Con M20 | 14 | $1,385 | $99 |
| Digoxin | 36 | $1,123 | $31 |
| Amiodarone | 37 | $1,056 | $29 |
| Furosemide | 82 | $1,025 | $12 |
| Sotalol | 30 | $995 | $33 |
| Losartan | 61 | $763 | $13 |
| Clopidogrel | 26 | $655 | $25 |
| Metoprolol | 23 | $655 | $28 |
| Carvedilol | 56 | $615 | $11 |
| Lisinopril | 46 | $600 | $13 |
| Isosorbide Mononitrate Er | 49 | $574 | $12 |
| Metoprolol | 65 | $567 | $9 |
| Spironolactone | 38 | $483 | $13 |
| Verapamil | 12 | $420 | $35 |
| Amlodipine Besylate | 34 | $360 | $11 |
| Pravastatin | 11 | $340 | $31 |
| Hydralazine | 11 | $301 | $27 |
| Rosuvastatin | 12 | $184 | $15 |
| Atenolol | 18 | $183 | $10 |
| Amoxicillin | 17 | $106 | $6 |
2018: 23 drugs
| Pradaxa | 53 | $28,105 | $530 |
| Ranexa | 16 | $16,220 | $1,014 |
| Flecainide Acetate | 101 | $6,029 | $60 |
| Bisoprolol | 88 | $3,353 | $38 |
| Dilt-Xr | 37 | $1,894 | $51 |
| Atorvastatin | 64 | $1,769 | $28 |
| Digoxin | 50 | $1,694 | $34 |
| Hydralazine | 12 | $1,112 | $93 |
| Losartan | 62 | $1,100 | $18 |
| Metoprolol | 110 | $1,059 | $10 |
| Lisinopril | 79 | $1,037 | $13 |
| Furosemide | 75 | $1,036 | $14 |
| Clopidogrel | 24 | $708 | $29 |
| Amiodarone | 30 | $617 | $21 |
| Isosorbide Mononitrate Er | 47 | $612 | $13 |
| Carvedilol | 52 | $606 | $12 |
| Sotalol | 26 | $392 | $15 |
| Diltiazem | 17 | $368 | $22 |
| Pantoprazole | 11 | $300 | $27 |
| Nitroglycerin | 15 | $299 | $20 |
| Amlodipine Besylate | 36 | $269 | $7 |
| Atenolol | 16 | $233 | $15 |
| Spironolactone | 11 | $102 | $9 |
2017: 27 drugs
| Pradaxa | 88 | $30,085 | $342 |
| Ranexa | 27 | $24,755 | $917 |
| Digoxin | 73 | $7,116 | $97 |
| Flecainide Acetate | 77 | $5,402 | $70 |
| Klor-Con M20 | 17 | $3,848 | $226 |
| Bisoprolol | 94 | $3,484 | $37 |
| Atorvastatin | 106 | $3,147 | $30 |
| Losartan | 80 | $1,838 | $23 |
| Dilt-Xr | 30 | $1,620 | $54 |
| Metoprolol | 153 | $1,556 | $10 |
| Furosemide | 106 | $1,467 | $14 |
| Lisinopril | 101 | $1,465 | $15 |
| Amiodarone | 51 | $1,340 | $26 |
| Metolazone | 21 | $1,029 | $49 |
| Pantoprazole | 27 | $906 | $34 |
| Isosorbide Mononitrate Er | 67 | $897 | $13 |
| Hydralazine | 12 | $891 | $74 |
| Clopidogrel | 25 | $791 | $32 |
| Carvedilol | 63 | $731 | $12 |
| Diltiazem | 17 | $525 | $31 |
| Atenolol | 35 | $519 | $15 |
| Sotalol | 25 | $418 | $17 |
| Pravastatin | 13 | $390 | $30 |
| Amlodipine Besylate | 46 | $376 | $8 |
| Torsemide | 12 | $347 | $29 |
| Nitroglycerin | 16 | $322 | $20 |
| Spironolactone | 36 | $317 | $9 |
2016: 26 drugs
| Pradaxa | 112 | $25,418 | $227 |
| Ranexa | 15 | $12,968 | $865 |
| Flecainide Acetate | 54 | $6,393 | $118 |
| Digoxin | 41 | $4,481 | $109 |
| Bisoprolol | 84 | $4,132 | $49 |
| Atorvastatin | 120 | $4,063 | $34 |
| Diltiazem 12hr Er | 14 | $2,168 | $155 |
| Lisinopril | 145 | $1,988 | $14 |
| Furosemide | 154 | $1,929 | $13 |
| Klor-Con M20 | 16 | $1,874 | $117 |
| Losartan | 71 | $1,869 | $26 |
| Nitrostat | 34 | $1,758 | $52 |
| Metoprolol | 142 | $1,498 | $11 |
| Carvedilol | 103 | $1,206 | $12 |
| Amiodarone | 41 | $1,128 | $28 |
| Dilt-Xr | 19 | $1,124 | $59 |
| Amlodipine Besylate | 60 | $826 | $14 |
| Pravastatin | 18 | $790 | $44 |
| Isosorbide Mononitrate Er | 63 | $788 | $13 |
| Pantoprazole | 24 | $772 | $32 |
| Clopidogrel | 21 | $737 | $35 |
| Atenolol | 55 | $708 | $13 |
| K-Tab Er | 20 | $472 | $24 |
| Spironolactone | 30 | $263 | $9 |
| Sotalol | 15 | $235 | $16 |
| Lisinopril-Hydrochlorothiazide | 12 | $140 | $12 |
2015: 24 drugs
| Ranexa | 24 | $14,523 | $605 |
| Pradaxa | 50 | $12,289 | $246 |
| Flecainide Acetate | 38 | $5,210 | $137 |
| Bisoprolol | 64 | $4,559 | $71 |
| Atorvastatin | 58 | $1,987 | $34 |
| Furosemide | 116 | $1,511 | $13 |
| Amiodarone | 47 | $1,439 | $31 |
| Digoxin | 16 | $1,377 | $86 |
| Losartan | 44 | $1,271 | $29 |
| Metolazone | 12 | $1,059 | $88 |
| Pantoprazole | 36 | $1,048 | $29 |
| Lisinopril | 71 | $961 | $14 |
| Atenolol | 73 | $942 | $13 |
| Clopidogrel | 17 | $930 | $55 |
| Metoprolol | 87 | $857 | $10 |
| Torsemide | 17 | $839 | $49 |
| Pravastatin | 19 | $815 | $43 |
| Nitrostat | 19 | $692 | $36 |
| Amlodipine Besylate | 29 | $626 | $22 |
| Isosorbide Mononitrate Er | 46 | $603 | $13 |
| Carvedilol | 48 | $593 | $12 |
| Hydralazine | 17 | $461 | $27 |
| K-Tab Er | 15 | $352 | $23 |
| Amoxicillin | 21 | $143 | $7 |
2014: 7 drugs
| Atorvastatin | 21 | $819 | $39 |
| Losartan | 15 | $405 | $27 |
| Carvedilol | 24 | $285 | $12 |
| Furosemide | 22 | $284 | $13 |
| Metoprolol | 22 | $220 | $10 |
| Isosorbide Mononitrate Er | 15 | $208 | $14 |
| Atenolol | 11 | $102 | $9 |
Money from drug and device companies
$1,343 in 2025
| 2025 | 13 | 27 | None | $1,343 |
| 2024 | 10 | 25 | None | $1,178 |
| 2023 | 6 | 13 | None | $468 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Abbott Laboratories | Cardiomems | $351 | 4 payments
|
| Medtronic | Symplicity G3 | $201 | 3 payments
|
| Heartflow | Ffrct | $181 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $177 | 3 payments
|
| E.R. Squibb & Sons L.L.C. | Eliquis | $158 | 6 payments
|
| Pfizer | Vyndaqel | $50 | 2 payments
|
See all 27 published payments
| Medtronic | Meals · 2025-12-19 | Symplicity G3 | $114 |
| Pfizer | Meals · 2025-12-17 | Vyndaqel | $26 |
| Abbott Laboratories | Meals · 2025-12-16 | Cardiomems | $166 |
| Abbott Laboratories | Meals · 2025-12-14 | Cardiomems | $36 |
| Abbott Laboratories | Meals · 2025-12-14 | Cardiomems | $122 |
| Edwards Lifesciences | Meals · 2025-12-09 | Sapien 3 Ultra Resilia | $47 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-11-24 | Camzyos | $6 |
| Heartflow | Meals · 2025-10-28 | Ffrct | $168 |
| Lilly USA | Meals · 2025-10-16 | Zepbound | $29 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-09-25 | Eliquis | $6 |
| Amgen | Meals · 2025-09-24 | Repatha | $32 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-08-18 | Jardiance | $32 |
| Pfizer | Meals · 2025-08-08 | Vyndaqel | $24 |
| Abbott Laboratories | Meals · 2025-07-21 | Amplatzer Amulet | $27 |
| Medtronic | Meals · 2025-05-27 | Micra | $52 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-14 | None | $118 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-06 | Eliquis | $22 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-05-06 | Eliquis | $1 |
| Stryker | Meals · 2025-04-29 | Flowtriever Catheter, S | $42 |
| Philips North America | Meals · 2025-04-18 | Mcot | $46 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Meals · 2025-03-18 | Lifevest | $6 |
| Medtronic | Meals · 2025-03-04 | Micra | $36 |
| Heartflow | Meals · 2025-02-19 | Ffrct | $13 |
| Esperion Therapeutics | Meals · 2025-02-11 | Nexletol | $22 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-02-06 | Jardiance | $33 |
| E.R. Squibb & Sons L.L.C. | Meals · 2025-01-16 | Camzyos | $6 |
| Boehringer Ingelheim Pharmaceuticals | Meals · 2025-01-07 | Jardiance | $112 |
See earlier years (2024, 2023)
2024: $1,178
| E.R. Squibb & Sons L.L.C. | Camzyos | $311 | 8 payments
|
| Abiomed | Impella | $311 | 2 payments
|
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $147 | 3 payments
|
| Edwards Lifesciences | Edwards Sapien 3 Ultra Transcatheter Heart Valve | $140 | 1 payment
|
| Heartflow | Ffrct | $72 | 2 payments
|
| Medtronic | Symplicity G3 | $66 | 1 payment
|
| Philips North America | (5044) Mcot | $56 | 2 payments
|
| iRhythm Technologies | Zio Xt Patch | $41 | 2 payments
|
| Sanofi-Aventis U.S. | Multaq | $18 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $17 | 3 payments
|
2023: $468
| Boehringer Ingelheim Pharmaceuticals | Jardiance | $162 | 3 payments
|
| Boston Scientific | Watchman Flx | $157 | 3 payments
|
| HeartFlow | Ffrct | $94 | 1 payment
|
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Lifevest | $26 | 4 payments
|
| AstraZeneca Pharmaceuticals LP | Farxiga | $16 | 1 payment
|
| iRhythm Technologies | Zio Xt Patch | $13 | 1 payment
|
Professional record
- NPI
- 1922252725
- Licence
- CA A109735California A109735: Current · expires 2027-05-31
- Trained
- Indiana University School of Medicine, 2008
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- Yes
- Taxonomy
- Cardiology (207RC0000X)
- Mailing address
- 34 Mark West Springs Rd Fl 3, Santa Rosa, CA, 95403
- NPI first listed
- 2008-11-06
- NPI last updated
- 2023-06-17
- NPI record certified
- 2023-06-17
This is when the NPI record was last certified, not a medical board exam.
This office lists an electronic records connection.